Where is S.A headquartered?

S.A. is recorded with headquarters in San Lorenzo, EU in NovaPharmaNews public regulatory and sponsor datasets.

Is S.A publicly traded?

Yes — S.A is listed as a public company with ticker CRSP on NYSE in SEC EDGAR-derived records.

What drugs are associated with S.A?

We link 7 drug profile(s) where S.A appears as originator or marketer in FDA or regional approval metadata.

What clinical trials is S.A sponsoring?

S.A is linked to 14 pipeline program(s) sourced from ClinicalTrials.gov and EU CTIS where sponsor names match.

What patents list S.A as applicant?

65 USPTO PatentsView record(s) name S.A. or a normalized variant as applicant.

What pipeline phases does S.A have in our database?

Phase distribution from linked programs: phase 1: 7, phase 2: 5, phase 3: 2.

How many US-approved drugs are linked to S.A?

4 linked drug profile(s) include US approval status in openFDA-derived metadata.

Does S.A hold EU marketing authorisations in our data?

7 linked drug(s) include EMA EPAR approval metadata.

Where does NovaPharmaNews source data on S.A?

Profiles combine SEC EDGAR (US issuers), FDA openFDA, EMA medicines data, ClinicalTrials.gov, EU CTIS, USPTO PatentsView, and regional PBS/PMDA/NMPA feeds. See /about/data-sources.

Is S.A data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

S.A Pharmaceuticals Company Profile | Pipeline, Drugs, Clinical…

Name: S.A intelligence dataset
Creator: NovaPharmaNews
License: https://www.sec.gov/edgar.shtml

Company details

Status: Public
HQ: San Lorenzo, EU
Founded: 2011
Employees: 50
Programs: 14
Drugs: 8
Patents: 65

Official website ↗ All projects Drug pipeline Patents News & analysis

Quick answer

S.A is a pharma organization headquartered in San Lorenzo, EU. It trades on NYSE under ticker CRSP. Primary therapeutic focus areas include T Cell Lymphoma, Diabetes Mellitus, Beta-Thalassemia, Sickle Cell Disease, B-cell Malignancy. NovaPharmaNews links 14 clinical program(s), 7 drug profile(s), and 65 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (7), phase 2 (5), phase 3 (2).

Company snapshot

Somos una empresa especializada en el desarrollo y producción de soluciones biotecnológicas. Nuestros productos están destinados a optimizar procesos industriales. Y, por consiguiente, a disminuir el impacto sobre el medio ambiente. Para esto, combinamos herramientas de ingeniería genética, biología sintética y técnicas de evolución dirigida. De este modo, trabajamos para convertirnos en aliados d

11 approved product(s) across US/EU regulatory metadata.
14 active pipeline program(s) linked via ClinicalTrials.gov.
65 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for S.A. Not investment advice.

Top assets

View drugs (8) View projects (14)

Lead pipeline drugs

eslicarbazepine acetate
approved
human fibrinogen
Marketed / approved
ketoconazole
approved
lebrikizumab
Marketed / approved

Active clinical programs

CTX001 Beta-Thalassemia
Phase 3
CTX001 Sickle Cell Disease
Phase 3
CTX110 B-cell Malignancy
Phase 2
CTX112 Warm Autoimmune Hemolytic Anemia (WAIHA)
Phase 2

Momentum

Proprietary activity score for S.A.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

Clinical trials 17 30d
Nova articles 0 30d
Patents filed 0 30d
FDA actions 0 30d
SEC filings 0 30d
Conference presentations 0 90d
Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Peer + 0 momentum

Takeda

TA overlap score 40
Peer + 0 momentum

Celgene

TA overlap score 29

Recent activity

Latest pipeline, patent, and corporate events for S.A.

Jun 5, 2026 Clinical update
CTX131 — Phase 2
Jun 5, 2026 Clinical update
CTX130 — Phase 1
May 23, 2026 Clinical update
CTX001 — Phase 3
May 23, 2026 Clinical update
CTX001 — Phase 3
May 23, 2026 Clinical update
CTX110 — Phase 2

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

What is S.A?

S.A is a pharma organization headquartered in San Lorenzo, EU. It trades on NYSE under ticker CRSP. Primary therapeutic focus areas include T Cell Lymphoma, Diabetes Mellitus, Beta-Thalassemia, Sickle Cell Disease, B-cell Malignancy. NovaPharmaNews links 14 clinical program(s), 7
Is S.A publicly traded?

Yes. S.A is listed with ticker CRSP on NYSE per SEC EDGAR records linked on this profile.
What drugs does S.A develop or market?

We link 8 drug profile(s) where S.A is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/crispr-therapeutics-ag#company-drugs.
What are the latest developments for S.A?

In the last 12 months our linked public records show 14 trial program update(s) and 3 US patent grant(s) tied to this profile.
What therapeutic areas does S.A focus on?

S.A focuses on T Cell Lymphoma, Diabetes Mellitus, Beta-Thalassemia based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others

Immunology

Cardiology

Neurology

Infectious Disease